<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722952</url>
  </required_header>
  <id_info>
    <org_study_id>SOOCHOW-HY-2020</org_study_id>
    <nct_id>NCT04722952</nct_id>
  </id_info>
  <brief_title>PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML</brief_title>
  <official_title>an Single Center，Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1&#xD;
      Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for&#xD;
      patients with relapsed and refractory acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment for Acute Myeloid Leukemia（AML） that has not responded to treatment (refractory) or&#xD;
      has returned after treatment (relapsed) often do not work. Researchers want to see if an&#xD;
      immunotherapy drug, combined with a less intense chemotherapy, may be able to help.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission， Incomplete blood count recovery，Partial remission（CR+CRi+PR）</measure>
    <time_frame>8 months</time_frame>
    <description>Number of Participants (Responders) Achieving CR+CRi+PR After the Eighth Cycle Treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate （ORR）</measure>
    <time_frame>8 months</time_frame>
    <description>Number of Participants (Responders) Achieving Overall Response Rate(ORR) After the Eighth Cycle Treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival（EFS）</measure>
    <time_frame>3 years</time_frame>
    <description>The time between the beginning of the group and the occurrence of any event, including death, progression of the disease, chemotherapy regimen, conversion to chemotherapy, addition of other treatment, occurrence of fatal or intolerable side effects, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>3 years</time_frame>
    <description>Time between the beginning of randomization and the progression (in any way) of tumorigenesis or (for any reason) death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immunotherapy</condition>
  <condition>Refractory Leukemia</condition>
  <condition>Relapsed Adult AML</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Anti-PD-1 mAb Combined With Azacytidine and HAG regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-PD-1 mAb combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visilizumab</intervention_name>
    <description>Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) &gt; 5X109／L or white blood cell（WBC）&gt; 20X109／L.</description>
    <arm_group_label>Anti-PD-1 mAb Combined With Azacytidine and HAG regimen</arm_group_label>
    <other_name>Azacytidine</other_name>
    <other_name>Homoharringtonine</other_name>
    <other_name>Cytarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chinese guidelines for the diagnosis and treatment of relapsed and refractory acute&#xD;
             myeloid leukemia (2017 edition)，excludes acute promyelocytic leukemia (M3、APL)&#xD;
&#xD;
               -  Hematopoietic stem cell transplantation ≥3 months, Discontinue immunosuppressant&#xD;
                  ≥3 weeks, Patients without graft-versus-host disease；&#xD;
&#xD;
               -  Be at least 18 years of age on day of signing informed consent.&#xD;
&#xD;
               -  Have a performance status of less than or equal to 2 on the Eastern Cooperative&#xD;
                  Oncology Group（ECOG） Performance Scale&#xD;
&#xD;
               -  Demonstrate adequate organ function as defined below, all screening labs should&#xD;
                  be performed before treatment initiation：&#xD;
&#xD;
                    1. ALT(SGPT) less than or equal to 2.5 × Upper Limit of Norma（ULN）；&#xD;
&#xD;
                    2. AST (SGOT) less than or equal to 2.5 × ULN；&#xD;
&#xD;
                    3. Serum total bilirubin Less than or equal to 2.0 × ULN Note: If total&#xD;
                       bilirubin &gt;2.0×ULN, subjects with Gilbert syndrome records are allowed to&#xD;
                       join the group&#xD;
&#xD;
                    4. Serum Creatinine ≥ 30 mL/min&#xD;
&#xD;
                    5. Total white blood cell (WBC) count ≤10,000/µL； Note: hydroxyurea therapy is&#xD;
                       allowed to reduce white blood cells to meet this inclusion criteria.white&#xD;
                       blood cells should be determined ≥24 hours after the last hydroxyurea&#xD;
                       administration. Final hydroxyurea administration should not ≤3 days prior to&#xD;
                       the first azacytidine administration.&#xD;
&#xD;
               -  Treatment without anthracycline or demethylation. Ability to comprehend the&#xD;
                  investigational nature of the study and provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic myeloid leukemia，AML of other myeloproliferative disorders&#xD;
             Malignant neoplasms with other progression Those who can not control severe infections&#xD;
             and other underlying diseases can not tolerate chemotherapy Patients with cardiac&#xD;
             insufficiency： ejection fraction (EF)&lt;30%，New York Heart Association（NYHA）&#xD;
             standards，Cardiac insufficiency II or above Patients with liver and kidney&#xD;
             dysfunction：Serum bilirubin (SB)≥2mg/dl，AST is 2.5 times higher than normal upper&#xD;
             limit, serum creatinine (SCr) is more than 2.5 mg/dl Serious mental illness&#xD;
             uncooperative Refusal to join the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Yue, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han Yue, Ph.D</last_name>
    <phone>(0086)51267781856</phone>
    <email>hanyue@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wu Depei, Ph.D</last_name>
    <phone>(0086)51267781856</phone>
    <email>drwudepei@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Han, professor</last_name>
      <phone>+86 13901551669</phone>
      <email>hanyuesz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015 Jul 16;126(3):319-27. doi: 10.1182/blood-2014-10-551911. Epub 2015 Apr 7. Review.</citation>
    <PMID>25852056</PMID>
  </reference>
  <reference>
    <citation>Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-4. doi: 10.1016/j.leukres.2010.09.002. Epub 2010 Nov 24.</citation>
    <PMID>21109304</PMID>
  </reference>
  <reference>
    <citation>Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.</citation>
    <PMID>31200351</PMID>
  </reference>
  <reference>
    <citation>Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12;21(35):5483-95. Review.</citation>
    <PMID>12154409</PMID>
  </reference>
  <reference>
    <citation>Keating GM. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. Review.</citation>
    <PMID>19911860</PMID>
  </reference>
  <reference>
    <citation>Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively. Asian Pac J Cancer Prev. 2015;16(15):6627-32.</citation>
    <PMID>26434886</PMID>
  </reference>
  <reference>
    <citation>Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, Grønbæk K. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget. 2015 Apr 20;6(11):9612-26.</citation>
    <PMID>25823822</PMID>
  </reference>
  <reference>
    <citation>Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.</citation>
    <PMID>30409776</PMID>
  </reference>
  <reference>
    <citation>Ivanoff S, Gruson B, Chantepie SP, Lemasle E, Merlusca L, Harrivel V, Charbonnier A, Votte P, Royer B, Marolleau JP. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol. 2013 Jul;88(7):601-5. doi: 10.1002/ajh.23464. Epub 2013 May 30.</citation>
    <PMID>23619977</PMID>
  </reference>
  <reference>
    <citation>Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.</citation>
    <PMID>25524177</PMID>
  </reference>
  <reference>
    <citation>Santini V, Ossenkoppele GJ. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Crit Rev Oncol Hematol. 2019 Aug;140:1-7. doi: 10.1016/j.critrevonc.2019.05.013. Epub 2019 May 25. Review.</citation>
    <PMID>31153036</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Refractory or Relapsed</keyword>
  <keyword>Azacytidine</keyword>
  <keyword>HAG regimen</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Homoharringtonine</mesh_term>
    <mesh_term>Visilizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04722952/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

